141 related articles for article (PubMed ID: 37354357)
1. An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma.
Adile AA; Bakhshinyan D; Suk Y; Uehling D; Saini M; Aman A; Magolan J; Subapanditha MK; McKenna D; Chokshi C; Savage N; Kameda-Smith MM; Venugopal C; Singh SK
J Neurooncol; 2023 Jul; 163(3):635-645. PubMed ID: 37354357
[TBL] [Abstract][Full Text] [Related]
2. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
3. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma.
Endersby R; Whitehouse J; Pribnow A; Kuchibhotla M; Hii H; Carline B; Gande S; Stripay J; Ancliffe M; Howlett M; Schoep T; George C; Andradas C; Dyer P; Schluck M; Patterson B; Tacheva-Gigorova SK; Cooper MN; Robinson G; Stewart C; Pfister SM; Kool M; Milde T; Gajjar A; Johns T; Wechsler-Reya RJ; Roussel MF; Gottardo NG
Sci Transl Med; 2021 Jan; 13(577):. PubMed ID: 33472956
[TBL] [Abstract][Full Text] [Related]
5. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
6. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
[TBL] [Abstract][Full Text] [Related]
7. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
8. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
9. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
10. CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Campagne O; Davis A; Maharaj AR; Zhong B; Stripay J; Farmer D; Roussel MF; Stewart CF
Eur J Pharm Sci; 2020 Jan; 142():105106. PubMed ID: 31669383
[TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of human medulloblastoma dissemination in the developing chick embryo nervous system.
Cage TA; Louie JD; Liu SR; Alvarez-Buylla A; Gupta N; Hyer J
Clin Exp Metastasis; 2012 Apr; 29(4):371-80. PubMed ID: 22322278
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
13. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
14. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
15. Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.
Fallon I; Hernando H; Almacellas-Rabaiget O; Marti-Fuster B; Spadoni C; Bigner DD; Méndez E
SLAS Discov; 2024 Mar; 29(2):100147. PubMed ID: 38355016
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
Teo WY; Elghetany MT; Shen J; Man TK; Li X; Chintagumpala M; Su JM; Dauser R; Whitehead W; Adesina AM; Lau CC
J Neurooncol; 2014 Nov; 120(2):293-301. PubMed ID: 25115738
[TBL] [Abstract][Full Text] [Related]
17. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
18. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma.
Yang WQ; Senger D; Muzik H; Shi ZQ; Johnson D; Brasher PM; Rewcastle NB; Hamilton M; Rutka J; Wolff J; Wetmore C; Curran T; Lee PW; Forsyth PA
Cancer Res; 2003 Jun; 63(12):3162-72. PubMed ID: 12810644
[TBL] [Abstract][Full Text] [Related]
19. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.
Garzia L; Andolfo I; Cusanelli E; Marino N; Petrosino G; De Martino D; Esposito V; Galeone A; Navas L; Esposito S; Gargiulo S; Fattet S; Donofrio V; Cinalli G; Brunetti A; Vecchio LD; Northcott PA; Delattre O; Taylor MD; Iolascon A; Zollo M
PLoS One; 2009; 4(3):e4998. PubMed ID: 19308264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
